Lupin signs distribution agreement with Celnova for Orphan Drug NaMuscla

Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia

Lupin announced that its subsidiary Lupin Atlantis Holdings has entered into a distribution agreement with Celnova Pharma (Celnova) for Lupin’s orphan drug NaMuscla (mexiletine). Celnova will commercialise NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla is the first and only licensed product in Europe for this indication.

Celnova will be the exclusive distributor of NaMuscla in Argentina and Colombia, and drive the registration, importation, storage, and sales. Celnova will leverage its regional expertise in managing patient-centric initiatives, particularly in the area of rare diseases, to ensure patients have access to this treatment. Lupin will manufacture and supply the finished products to Celnova.

“This is a significant step for Lupin as we introduce NaMuscla in two of our key Latin American markets. This is aligned to our commitment of meeting the needs of NDM patients by creating tailor-made solutions for each market, working with health authorities, healthcare providers, patient advocacy groups to help patients suffering from myotonia diseases,” said Dr Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.

"We are excited to partner with Lupin to bring NaMuscla® to patients in Argentina and Colombia. This collaboration addresses a significant unmet need for those living with non-dystrophic myotonic disorders, offering an innovative treatment option that can greatly improve their quality of life. At Celnova, we are dedicated to providing advanced therapies that enhance patient outcomes, and this agreement reinforces our commitment to making a positive impact in rare diseases,” said Juan Marrone, CEO, Celnova.